Neuraxis, INCNRXSEarnings & Financial Report
Neuraxis, Inc. is a clinical-stage biopharmaceutical company focused on researching, developing and commercializing innovative therapies for central nervous system disorders such as chronic neuropathic pain, addressing unmet neurological care needs across North American and select European markets.
NRXS Q4 FY2025 Key Financial Metrics
Revenue
$968.1K
Gross Profit
$826.8K
Operating Profit
$-1.7M
Net Profit
$-1.7M
Gross Margin
85.4%
Operating Margin
-177.3%
Net Margin
-176.5%
YoY Growth
27.2%
EPS
$-0.16
Neuraxis, INC Q4 FY2025 Financial Summary
Neuraxis, INC reported revenue of $968.1K (up 27.2% YoY) for Q4 FY2025, with a net profit of $-1.7M (down 18.0% YoY) (-176.5% margin). Cost of goods sold was $141.3K, operating expenses totaled $2.5M.
Key Financial Metrics
| Total Revenue | $968.1K |
|---|---|
| Net Profit | $-1.7M |
| Gross Margin | 85.4% |
| Operating Margin | -177.3% |
| Report Period | Q4 FY2025 |
Neuraxis, INC Annual Revenue by Year
Neuraxis, INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $3.6M).
Neuraxis, INC Quarterly Revenue & Net Profit History
Neuraxis, INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $968.1K | +27.2% | $-1.7M | -176.5% |
| Q3 FY2025 | $811.4K | +21.7% | $-2.1M | -261.6% |
| Q2 FY2025 | $894.1K | +46.2% | $-1.7M | -189.1% |
| Q1 FY2025 | $895.7K | +38.5% | $-2.3M | -254.4% |
| Q4 FY2024 | $761.2K | — | $-1.4M | -190.2% |
| Q3 FY2024 | $666.6K | +39.6% | $-1.8M | -263.3% |
| Q2 FY2024 | $611.5K | -5.3% | $-2.9M | -477.1% |
| Q1 FY2024 | $646.6K | — | $-2.1M | -328.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $646635 | $611500 | $666625 | $761165 | $895655 | $894086 | $811414 | $968127 |
| YoY Growth | N/A | -5.3% | 39.6% | N/A | 38.5% | 46.2% | 21.7% | 27.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $945729 | $2.6M | $1.1M | $4.8M | $3.0M | $7.1M | $5.8M | $6.4M |
| Liabilities | $4.1M | $7.9M | $2.9M | $2.7M | $2.8M | $2.8M | $3.5M | $3.0M |
| Equity | $-3.2M | $-5.3M | $-1.8M | $2.1M | $258479 | $4.3M | $2.3M | $3.4M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.3M | $-1.6M | $-1.4M | $-1.8M | $-1.6M | $-1.5M | $-1.4M | $-1.9M |